Antimicrobial Combinations, Cystic Fibrosis Panel
Test Code
16406
87181 (x34)
CPT Code is subject to a Medicare Limited Coverage Policy and may require a signed ABN when ordering.
Clinical Significance
Antimicrobial Combinations, Cystic Fibrosis Panel - The use of antimicrobial combinations for the treatment of infectious diseases has become more common due to several factors including: more severe infections, development of organism resistance, and infection with multiple organisms. Antimicrobial combinations may help to expand the spectrum of coverage, minimize drug toxicity, minimize development of resistance, and may lead to antimicrobial combination synergy.
Test Resources
None found for this test
Please visit our Clinical Education Center to stay informed on any future publications, webinars, or other education opportunities.
Please visit our Clinical Education Center to stay informed on any future publications, webinars, or other education opportunities.
Test Details
Piperacillin and Tobramycin; Tobramycin and Meropenem; Tobramycin and Ceftazidime; Tobramycin and Ticar/Clav; Tobramycin and Imipenem; Tobramycin and Aztreonam; Meropenem and Amikacin; Imipenem and Ciprofloxacin; Ceftazidime and Amikacin; Meropenem and Ciprofloxacin; Piperacillin and Ciprofloxacin; Cefepime and Tobramycin
Methodology
Antibiotic Gradient
Reference Range(s)
See Laboratory Report
Preferred Specimen(s)
Pure isolate of Pseudomonas aeruginosa on a slant or transport swab
Transport Container
Double-walled container
Transport Temperature
Room temperature
Specimen Stability
- Room temperature: Determined by viability
- Refrigerated: Determined by viability
- Frozen: Unacceptable
Reject Criteria
Received frozen
Setup Schedule
Pure isolate of Pseudomonas aeruginosa on a slant or transport swab
Double-walled container
Room temperature
Room temperature: Determined by viability
Refrigerated: Determined by viability
Frozen: Unacceptable
Refrigerated: Determined by viability
Frozen: Unacceptable
Received frozen